NEW YORK (GenomeWeb News) - Canadian biomarker developer Med BioGene has hired an investment advisory and financial services company and has granted some of its executives options to buy up to 560,000 common shares at Can$.34 ($.32) a share, the company said today.
 
The Vancouver, BC-based MBI said it has hired Peterson Capital, an investment, financial services, and communications firm, for a monthly cash rate and the option to buy up to 100,000 shares at Can$.34 a share.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Associated Press reports that the US government wasted $341,000 on travel by former Health and Human Services Secretary Tom Price.

Women who post YouTube science videos get more critical comments and more comments about their appearance than male video hosts, the New York Times reports.

The Wall Street Journal writes that participating in genetic research brings up the specter of past research ethics lapses for some African Americans.

In PLOS this week: sequences influencing yeast prion aggregation or degradation, dengue virus genetic variants affect transmission dynamics, and more.